- Merck KGaA, Darmstadt, Germany has completed its $3.4 billion acquisition of SpringWorks Therapeutics following regulatory clearance.
- The transaction strengthens Merck KGaA’s position in rare tumours and is expected to contribute to earnings by 2027.
Merck KGaA, Darmstadt, Germany has announced the closing of its $3.4 billion (approximately €3 billion) acquisition of SpringWorks Therapeutics, Inc., a U.S.-based biopharmaceutical company focused on rare tumours. The transaction was finalised following regulatory approvals and customary closing conditions.
The deal, originally disclosed in April 2025, marks one of the largest M&A transactions in the global biopharma sector this year. Headquartered in Stamford, Connecticut, SpringWorks brings to Merck KGaA a commercial portfolio and late-stage assets targeting rare and debilitating tumour types.
“This is the largest acquisition we have made for our Healthcare business sector in nearly 20 years,” said Belén Garijo, Chair of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany. The company expects the deal to add to revenues immediately and to be accretive to earnings per share pre (EPS pre) by 2027.
SpringWorks’ portfolio includes OGSIVEO® (nirogacestat), FDA-approved for desmoid tumours, and GOMEKLI™ (mirdametinib), approved for the treatment of symptomatic plexiform neurofibromas in patients with neurofibromatosis type 1 (NF1). Both products have also received positive opinions from the European Medicines Agency’s CHMP.
This acquisition complements Merck KGaA’s existing pipeline, including pimicotinib for tenosynovial giant cell tumour, and underscores its strategic aim to build a strong presence in rare tumours. SpringWorks shares will no longer trade on Nasdaq, as Merck KGaA becomes its sole owner.
Stay ahead of trends and best practices
